Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Melanotransferrin antibody (MA) and tamoxifen (TX) were conjugated on etoposide (ETP)-entrapped solid lipid nanoparticles (ETP-SLNs) to target the blood-brain barrier (BBB) and glioblastom multiforme (GBM). MA- and TX-conjugated ETP-SLNs (MA-TX-ETP-SLNs) were used to infiltrate the BBB comprising a monolayer of human astrocyte-regulated human brain-microvascular endothelial cells (HBMECs) and to restrain the proliferation of malignant U87MG cells. TX-grafted ETP-SLNs (TX-ETP-SLNs) significantly enhanced the BBB permeability coefficient for ETP and raised the fluorescent intensity of calcein-AM when compared with ETP-SLNs. In addition, surface MA could increase the BBB permeability coefficient for ETP about twofold. The viability of HBMECs was higher than 86%, suggesting a high biocompatibility of MA-TX-ETP-SLNs. Moreover, the efficiency in antiproliferation against U87MG cells was in the order of MA-TX-ETP-SLNs > TX-ETP-SLNs > ETP-SLNs > SLNs. The capability of MA-TX-ETP-SLNs to target HBMECs and U87MG cells during internalization was verified by immunochemical staining of expressed melanotransferrin. MA-TX-ETP-SLNs can be a potent pharmacotherapy to deliver ETP across the BBB to GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Astrocyte-endothelial Interactions and Blood-Brain Barrier Permeability*
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00064.x · Cited by 1,168
Cited by
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“The anti-proliferation efficacy against U87MG cells was found to be in the order of MA-TX-ETP-SLNs[TXETP-SLNs[ETP-SLNs[ SLNs, revealing the potential of MA-TX-ETP-SLNs to deliver ETP across the BBB for the treatment of glioblastoma multiforme [140].”
BackgroundSolid lipid nanoparticles: a review on recent perspectives and patents
Paliwal, R., Paliwal, S. R., Kenwat, R., Kurmi, B. D., & Sahu, M. K. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1720649 · Cited by 337
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
“This could be attributed to the ability of these drug-loaded SLNs to infiltrate the BBB, suggesting their potential therapeutic use in future clinics for the treat-ment of multiple forms glioblastoma [245–249].”
Teixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2023) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112999 · Cited by 154
Metadata
- Authors
- Kuo, Y.-C., & Wang, I.-H.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2016-01-15
- Volume
- 24
- Issue
- 7
- Pages
- 645-654
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2228799646
- Cited by
- 52
- References
- 2
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles. https://app.cochat.ai/papers/10.3109/1061186x.2015.1132223
- The paper
- Kuo, Y.-C., & Wang, I.-H. (2016). Enhanced delivery of etoposide across the blood–brain barrier to restrain brain tumor growth using melanotransferrin antibody- and tamoxifen-conjugated solid lipid nanoparticles. Journal of Drug Targeting. https://doi.org/10.3109/1061186x.2015.1132223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.